This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wise, R.
Right arrow Articles by Marshall, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wise, R.
Right arrow Articles by Marshall, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2002, p. 31-33, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.31-33.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics and Inflammatory Fluid Penetration of Intravenous Daptomycin in Volunteers

R. Wise,1* T. Gee,1 J. M. Andrews,1 B. Dvorchik,2 and G. Marshall1

Department of Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom,1 Cubist Pharmaceuticals, Cambridge, Massachusetts2

Received 30 January 2001/ Returned for modification 15 July 2001/ Accepted 20 September 2001

The lipopeptide antimicrobial daptomycin was administered intravenously at a dose of 4 mg/kg of body weight to seven healthy male volunteers. The concentrations of daptomycin in plasma, cantharidin-induced inflammatory fluid, and urine were measured by a microbiological assay. The mean ± standard deviation peak concentrations in plasma and inflammatory fluid were 77.5 ± 8.3 and 27.6 ± 9.5 µg/ml, respectively; the mean terminal elimination half-lives were 7.74 and 13.2 h, respectively. The overall penetration of total drug into the inflammatory fluid (measured by ratio of the area under the concentration-time curve from 0 to 24 h for inflammatory fluid compared with that for plasma) was 68.4%. The mean urinary recovery over 24 h was 59.7%.

* Corresponding author. Mailing address: Department of Microbiology, City Hospital NHS Trust, Dudley Rd., Birmingham B18 7QH, United Kingdom. Phone: (0121) 507 4255. Fax: (0121) 551 7763. E-mail: r.wise{at}bham.ac.uk.

Antimicrobial Agents and Chemotherapy, January 2002, p. 31-33, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.31-33.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chakraborty, A., Roy, S., Loeffler, J., Chaves, R. L. (2009). Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 64: 151-158 [Abstract] [Full Text]  
  • John, A.-K., Baldoni, D., Haschke, M., Rentsch, K., Schaerli, P., Zimmerli, W., Trampuz, A. (2009). Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus: Importance of Combination with Rifampin. Antimicrob. Agents Chemother. 53: 2719-2724 [Abstract] [Full Text]  
  • Bubalo, J. S., Munar, M. Y., Cherala, G., Hayes-Lattin, B., Maziarz, R. (2009). Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever. Antimicrob. Agents Chemother. 53: 428-434 [Abstract] [Full Text]  
  • Kim, A., Suecof, L. A., Sutherland, C. A., Gao, L., Kuti, J. L., Nicolau, D. P. (2008). In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers. Antimicrob. Agents Chemother. 52: 3941-3946 [Abstract] [Full Text]  
  • Hawkey, P. M. (2008). Pre-clinical experience with daptomycin. J Antimicrob Chemother 62: iii7-iii14 [Abstract] [Full Text]  
  • Seaton, R. A. (2008). Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 62: iii15-iii23 [Abstract] [Full Text]  
  • LaPlante, K. L., Leonard, S. N., Andes, D. R., Craig, W. A., Rybak, M. J. (2008). Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant Staphylococcus aureus with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models. Antimicrob. Agents Chemother. 52: 2156-2162 [Abstract] [Full Text]  
  • Lemaire, S., Van Bambeke, F., Mingeot-Leclercq, M.-P., Tulkens, P. M. (2007). Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin towards Phagocytized Staphylococcus aureus by the P-Glycoprotein (MDR1) Efflux Transporter in Human THP-1 Macrophages and Madin-Darby Canine Kidney Cells. Antimicrob. Agents Chemother. 51: 2748-2757 [Abstract] [Full Text]  
  • Pai, M. P., Norenberg, J. P., Anderson, T., Goade, D. W., Rodvold, K. A., Telepak, R. A., Mercier, R.-C. (2007). Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin. Antimicrob. Agents Chemother. 51: 2741-2747 [Abstract] [Full Text]  
  • LaPlante, K. L., Rybak, M. J., Leuthner, K. D., Chin, J. N. (2006). Impact of Enterococcus faecalis on the Bactericidal Activities of Arbekacin, Daptomycin, Linezolid, and Tigecycline against Methicillin-Resistant Staphylococcus aureus in a Mixed-Pathogen Pharmacodynamic Model.. Antimicrob. Agents Chemother. 50: 1298-1303 [Abstract] [Full Text]  
  • Schriever, C. A., Fernandez, C., Rodvold, K. A., Danziger, L. H. (2005). Daptomycin: A novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62: 1145-1158 [Abstract] [Full Text]  
  • Steenbergen, J. N., Alder, J., Thorne, G. M., Tally, F. P. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55: 283-288 [Abstract] [Full Text]  
  • Huang, V., Rybak, M. J. (2005). Pharmacodynamics of Cefepime Alone and in Combination with Various Antimicrobials against Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model. Antimicrob. Agents Chemother. 49: 302-308 [Abstract] [Full Text]  
  • Cottagnoud, P., Pfister, M., Acosta, F., Cottagnoud, M., Flatz, L., Kuhn, F., Muller, H.-P., Stucki, A. (2004). Daptomycin Is Highly Efficacious against Penicillin-Resistant and Penicillin- and Quinolone-Resistant Pneumococci in Experimental Meningitis. Antimicrob. Agents Chemother. 48: 3928-3933 [Abstract] [Full Text]  
  • Dvorchik, B., Arbeit, R. D., Chung, J., Liu, S., Knebel, W., Kastrissios, H. (2004). Population Pharmacokinetics of Daptomycin. Antimicrob. Agents Chemother. 48: 2799-2807 [Abstract] [Full Text]  
  • Dvorchik, B., Damphousse, D. (2004). Single-Dose Pharmacokinetics of Daptomycin in Young and Geriatric Volunteers. J Clin Pharmacol 44: 612-620 [Abstract] [Full Text]  
  • Pankuch, G. A., Jacobs, M. R., Appelbaum, P. C. (2003). Postantibiotic Effects of Daptomycin against 14 Staphylococcal and Pneumococcal Clinical Isolates. Antimicrob. Agents Chemother. 47: 3012-3014 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Li, D., Lew, D. P., Schrenzel, J. (2003). Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 52: 89-95 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»